Jasper Therapeutics announced additional Phase 1b/2a data on briquilimab as a conditioning agent in the treatment of Fanconi Anemia. The data was presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium on March 13, 2024, in Palo Alto, California. The ongoing investigator initiated Phase 1b/2a clinical trial is evaluating a conditioning regimen that includes intravenous briquilimab as a potential treatment for FA patients in bone marrow failure. Data from the study show that briquilimab infusion has a promising safety profile and appears to be well tolerated in patients with FA, with all six patients treated achieving full donor engraftment and full blood count recovery.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JSPR:
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
- Bad News for Jasper Therapeutics, Inc. Stock: This New Risk Has Been Added
- Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
- Jasper Therapeutics reports Q4 EPS ($1.50), consensus ($1.61)
- Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
